NICE issues final draft guidance for use of molnupiravir for treatment of COVID-19
Final draft guidance for molnupiravir has been published by the National Institute for Health and Care Excellence (NICE).
The Scottish Medicines Consortium (SMC) has had direct input into the decision-making committee that produced the final draft guidance. SMC advice will be aligned with NICE final guidance.
The final draft guidance recommends molnupiravir as an option for treating mild to moderate COVID-19 in adults who have a positive SARS-CoV-2 test, only if:
- they have 1 or more risk factors for progression to severe COVID-19 (as defined in section 5 of NICE’s technology appraisal guidance on nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19) and
- both nirmatrelvir plus ritonavir and sotrovimab are contraindicated or unsuitable.
SMC will issue a collaborative advice document to boards following publication of the NICE final guidance. The advice will have the same status for health board consideration as other SMC advice on new medicines.
You can read more about the final draft guidance recommendations here: Project documents | Molnupiravir for treating COVID-19 [ID6340] | Guidance | NICE